136 related articles for article (PubMed ID: 26892152)
61. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
62. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
63. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
O'Sullivan CC; Connolly RM
Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
[TBL] [Abstract][Full Text] [Related]
64. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
Ibrahim EM; Kazkaz GA; Al-Mansour MM; Al-Foheidi ME
Breast Cancer Res Treat; 2015 Aug; 152(3):463-76. PubMed ID: 26105797
[TBL] [Abstract][Full Text] [Related]
65. Trastuzumab emtansine for HER2-positive breast cancer.
Venkatesan P
Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
[No Abstract] [Full Text] [Related]
66. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Azuma K; Tsurutani J; Sakai K; Kaneda H; Fujisaka Y; Takeda M; Watatani M; Arao T; Satoh T; Okamoto I; Kurata T; Nishio K; Nakagawa K
Biochem Biophys Res Commun; 2011 Apr; 407(1):219-24. PubMed ID: 21377448
[TBL] [Abstract][Full Text] [Related]
67. The immune system and response to HER2-targeted treatment in breast cancer.
Bianchini G; Gianni L
Lancet Oncol; 2014 Feb; 15(2):e58-68. PubMed ID: 24480556
[TBL] [Abstract][Full Text] [Related]
68. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
69. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
[TBL] [Abstract][Full Text] [Related]
70. Management of Neutropenic Toxicity From CDK4/6 Inhibitors.
Frinzi Byers K
Oncology (Williston Park); 2019 Jan; 33(1):26-7. PubMed ID: 30731015
[No Abstract] [Full Text] [Related]
71. Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.
Ihnenfeld Arciénega I; Imesch P; Fink D; Dedes KJ
Target Oncol; 2015 Jun; 10(2):297-301. PubMed ID: 25511015
[TBL] [Abstract][Full Text] [Related]
72. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
73. Gaining ground on breast cancer.
Esteva FJ; Hortobagyi GN
Sci Am; 2008 Jun; 298(6):58-65. PubMed ID: 18642543
[No Abstract] [Full Text] [Related]
74. Special issue: Current vision on target enzymes for cancer therapy.
Bishayee A; Kamal MA
Semin Cancer Biol; 2019 Jun; 56():iii-v. PubMed ID: 30503852
[No Abstract] [Full Text] [Related]
75. Selected Articles from This Issue.
Mol Cancer Ther; 2020 Jul; 19(7):1383. PubMed ID: 32616655
[No Abstract] [Full Text] [Related]
76. The MonarchE trial: improving the clinical outcome in HR
Bertucci F; Finetti P; Mamessier E; De Nonneville A
Cancer Commun (Lond); 2023 Aug; 43(8):938-942. PubMed ID: 37462449
[No Abstract] [Full Text] [Related]
77. Molecular targets in breast cancer: current status and future directions.
Cristofanilli M; Hortobagyi GN
Endocr Relat Cancer; 2002 Dec; 9(4):249-66. PubMed ID: 12542402
[TBL] [Abstract][Full Text] [Related]
78. Interpreting cancer biology: refining our therapeutic algorithm in breast cancer.
Hortobágyi G; Conte P
Oncologist; 2013; 18(4):e8-10. PubMed ID: 23633451
[No Abstract] [Full Text] [Related]
79. Evaluation of biological agents targeted at early-stage disease.
Guix M; Mayer IA; Meszoely IM; Arteaga CL
Breast Cancer Res; 2008; 10 Suppl 4(Suppl 4):S25. PubMed ID: 19128439
[No Abstract] [Full Text] [Related]
80. [Interpretation and analysis of the testing results of main molecular pathological markers in breast cancer].
Yang YL; Guo XJ; Fu L
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):526-528. PubMed ID: 32392947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
